Hem › Urotelial (övergångscells-)karcinom › Illinois › Chicago
Kliniska studier för Urotelial (övergångscells-)karcinom i Chicago, IL
14 studier för Urotelial (övergångscells-)karcinom söker deltagare vid platser i och runt Chicago (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekryterarFas 1
- Exelixis Clinical Site #26, Chicago
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
RekryterarFas 3
- University of Illinois, Chicago
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RekryterarFas 2
- Rush MD Anderson Cancer Center, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
RekryterarObservationsstudie
- Northwestern University, Chicago
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
RekryterarFas 1/2
- University of Chicago Medical Center ( Site 1037), Chicago
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RekryterarFas 3
- University of Illinois at Chicago, Chicago
- University of Chicago Medical Center, Chicago
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekryterarFas 1
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
RekryterarFas 2
- UChicago Medicine - River East, Chicago
- University of Chicago Medical Center, Chicago
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RekryterarFas 1/2
- The University of Chicago Medical Center - Oncology, Chicago
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
RekryterarFas 2
- Site 02-012 - University of Chicago, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekryterarObservationsstudie
- Massive Bio SYNERGY-AI site, Chicago
Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer
RekryterarObservationsstudie
- Jesse Brown Department Of Veterans Affairs Medical Center, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
RekryterarFas 1
- University of Chicago, Chicago
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
RekryterarFas 2
- Northwestern University, Chicago
Urotelial (övergångscells-)karcinom-studier i andra städer
- Nashville, TN23 studier
- New York City, NY22 studier
- Dallas, TX18 studier
- Edison, NJ18 studier
- Houston, TX18 studier
- Los Angeles, CA17 studier
- Queens, NY15 studier
- Arlington, VA12 studier
- San Antonio, TX11 studier
- Boston, MA11 studier
- Austin, TX10 studier
- Orange, CA10 studier
Andra studier i Chicago
- Icke-småcellig lungcancer61 studier
- Bröstcancer58 studier
- Cancer (alla typer)51 studier
- Metastaserande cancer45 studier
- Prostatacancer45 studier
- Övervikt41 studier
- Lungcancer41 studier
- Äggstockscancer36 studier
- Stroke34 studier
- Kolorektal cancer33 studier
- Hjärtsvikt31 studier
- Övervikt28 studier
Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.